The combination of anti-CD38 mAbs with main anti-MM drugs as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) demonstrated a high clinical efficacy in randomized phase III trials [5] leading to new therapeutic paradigms in relapsed/refractory MM patients. This evidence concerns the gene CD38 and Miyoshi myopathy.